Latest Peptides Stories

The ProImmune Company's Immune Formulation 200® Dietary Supplement, a novel Glutathione precursor which replenishes bodily Glutathione, also activates Nrf2. Nrf2 mobilizes approximately 250 immune support genes, a major asset to immune system support, The Glutathione synthesis pathway is also a route to Nrf2 activation. The study was reported in peer-reviewed Experimental and Molecular Pathology. (PRWEB) June 28, 2012 ProImmune's Immune Formulation 200® is able to potentiate...

BOONTON, N.J., May 21, 2012 /PRNewswire/ -- Unigene Laboratories, Inc. (OTCBB: UGNE), a leader in the design, delivery, manufacture and development of peptide-based therapeutics, today announced the Company's Vice President of Research and Development, Nozer Mehta, Ph.D., will be presenting at the TIDES 2012 conference for the oligonucleotide and peptide industry, being held at the Mandalay Bay Resort and Casino in Las Vegas, NV. TIDES 2012 is the premier conference focused on...

The U.S. Patent Trademark Office has issued a patent for a discovery involving a pleiotropic delivery system that can revolutionize Immune System support for physiological replenishment of Glutathione for The ProImmune Company. Rhinebeck, NY (PRWEB) April 05, 2012 The tripeptide Glutathione is considered the master antioxidant and primary protector of the Immune System. It protects the body from toxins and oxidative stress. Glutathione is synthesized intracellularly, in every cell of the...

Gold nanostars first to deliver drug directly to cancer cell nucleus Nanotechnology offers powerful new possibilities for targeted cancer therapies, but the design challenges are many. Northwestern University scientists now are the first to develop a simple but specialized nanoparticle that can deliver a drug directly to a cancer cell's nucleus -- an important feature for effective treatment. They also are the first to directly image at nanoscale dimensions how nanoparticles interact...

BASKING RIDGE, N.J., March 28, 2012 /PRNewswire/ -- Regado Biosciences, Inc., a privately held company leading the development of antithrombotic aptamers with active control agents, announced that David J. Mazzo, PhD, President and CEO, will be presenting at Needham & Company's 11th Annual Healthcare Conference at 10 a.m. EDT on April 4, 2012 at the New York Palace Hotel in New York City. The presentation will include an overview of the Company's pipeline with emphasis on the...

BASKING RIDGE, N.J., March 14, 2012 /PRNewswire/ -- Regado Biosciences, Inc., a privately held company leading the development of antithrombotic aptamers with active control agents, announced that David J. Mazzo, PhD, President and CEO, will be presenting at the BIO-Europe Spring® 2012 conference at 9:15 a.m. local time (3:15 a.m. EDT) on March 21, 2012 at the Amsterdam RAI Convention Center in Amsterdam, The Netherlands. The presentation will include an overview of the Company's...

BASKING RIDGE, N.J., Feb. 28, 2012 /PRNewswire/ -- Regado Biosciences, Inc., a privately held company leading the development of antithrombotic aptamers with active control agents, announced that David J. Mazzo, PhD, President and CEO, will be presenting at the Cowen and Company 32(nd) Annual Health Care Conference at 1:30 p.m. EST on March 5, 2012 at The Boston Marriott Copley Place in Boston, MA. The presentation will include an overview of the Company's pipeline with emphasis on...

BOONTON, N.J., Feb. 27, 2012 /PRNewswire/ -- Unigene Laboratories, Inc. (OTCBB: UGNE), a leader in the design, delivery, manufacture and development of peptide-based therapeutics, today announced the Company's Vice President of Research and Development, Nozer Mehta, Ph.D., will be presenting at IBC's 4th Annual AsiaTIDES Oligonucleotide and Peptide® Conference being held at the Sheraton Miyako Hotel in Tokyo, Japan. The TIDES Oligonucleotide and Peptide Conferences are the premier...

BASKING RIDGE, N.J., Feb. 22, 2012 /PRNewswire/ -- Regado Biosciences, Inc., a privately held company leading the development of antithrombotic aptamers with active control agents, announced that David J. Mazzo, PhD, President and CEO, will be presenting at the Citi 2012 Global Health Care Conference at 8:30 a.m. EST on February 29, 2012 at The Waldorf Astoria in New York, NY. The presentation will include an overview of the Company's pipeline with emphasis on the lead...

PALO ALTO, Calif., Feb. 8, 2012 /PRNewswire/ -- Telik, Inc. (Nasdaq: TELK) today announced that CEO Michael M. Wick, M.D., Ph.D. will provide a corporate overview at the 14(th) Annual BIO CEO & Investor Conference in New York City on Tuesday, February 14 at 1:00 p.m. Eastern time (10:00 a.m. Pacific time), in the Waldorf-Astoria Hotel's Conrad Suite. A live and archived webcast of the presentation will be available on the Telik website, www.telik.com. The archived broadcast of...